Cipher Pharmaceuticals Future Growth
Future criteria checks 2/6
Cipher Pharmaceuticals is forecast to grow earnings and revenue by 12.7% and 18.8% per annum respectively. EPS is expected to grow by 13.4% per annum. Return on equity is forecast to be 14.2% in 3 years.
Key information
12.7%
Earnings growth rate
13.4%
EPS growth rate
Pharmaceuticals earnings growth | 21.6% |
Revenue growth rate | 18.8% |
Future return on equity | 14.2% |
Analyst coverage | Low |
Last updated | 08 Nov 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 55 | 25 | N/A | 35 | 2 |
12/31/2025 | 50 | 23 | N/A | 26 | 3 |
12/31/2024 | 34 | 14 | N/A | 18 | 3 |
9/30/2024 | 26 | 16 | -67 | 13 | N/A |
6/30/2024 | 22 | 23 | 17 | 17 | N/A |
3/31/2024 | 22 | 23 | 14 | 14 | N/A |
12/31/2023 | 21 | 20 | 16 | 16 | N/A |
9/30/2023 | 21 | 32 | 15 | 15 | N/A |
6/30/2023 | 20 | 28 | 13 | 13 | N/A |
3/31/2023 | 20 | 27 | 13 | 13 | N/A |
12/31/2022 | 21 | 27 | 11 | 11 | N/A |
9/30/2022 | 22 | 10 | 15 | 15 | N/A |
6/30/2022 | 21 | 8 | 11 | 11 | N/A |
3/31/2022 | 22 | 9 | 11 | 11 | N/A |
12/31/2021 | 22 | 8 | 14 | 14 | N/A |
9/30/2021 | 22 | 5 | 14 | 14 | N/A |
6/30/2021 | 23 | 6 | 12 | 12 | N/A |
3/31/2021 | 21 | 3 | 11 | 11 | N/A |
12/31/2020 | 22 | 4 | 11 | 12 | N/A |
9/30/2020 | 21 | 7 | 7 | 7 | N/A |
6/30/2020 | 22 | 3 | 10 | 11 | N/A |
3/31/2020 | 23 | 4 | 11 | 12 | N/A |
12/31/2019 | 22 | 3 | 7 | 8 | N/A |
9/30/2019 | 23 | -1 | 6 | 8 | N/A |
6/30/2019 | 22 | 2 | 4 | 6 | N/A |
3/31/2019 | 23 | 3 | 0 | 2 | N/A |
12/31/2018 | 23 | 1 | 1 | 8 | N/A |
9/30/2018 | 28 | 6 | 7 | 13 | N/A |
6/30/2018 | 34 | 9 | N/A | 18 | N/A |
3/31/2018 | 37 | 11 | N/A | 19 | N/A |
12/31/2017 | 40 | 11 | N/A | 13 | N/A |
9/30/2017 | 34 | 7 | N/A | 11 | N/A |
6/30/2017 | 32 | 5 | N/A | 9 | N/A |
3/31/2017 | 31 | 1 | N/A | 10 | N/A |
12/31/2016 | 30 | 4 | N/A | 11 | N/A |
9/30/2016 | 33 | 6 | N/A | 8 | N/A |
6/30/2016 | 34 | 2 | N/A | 7 | N/A |
3/31/2016 | 34 | 1 | N/A | 7 | N/A |
12/31/2015 | 34 | 2 | N/A | 8 | N/A |
9/30/2015 | 32 | 3 | N/A | 12 | N/A |
6/30/2015 | 30 | 13 | N/A | 16 | N/A |
3/31/2015 | 30 | 18 | N/A | 19 | N/A |
12/31/2014 | 29 | 19 | N/A | 25 | N/A |
9/30/2014 | 33 | 31 | N/A | 23 | N/A |
6/30/2014 | 32 | 27 | N/A | 18 | N/A |
3/31/2014 | 29 | 25 | N/A | 15 | N/A |
12/31/2013 | 25 | 24 | N/A | 7 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: PHE's forecast earnings growth (12.7% per year) is above the savings rate (1%).
Earnings vs Market: PHE's earnings (12.7% per year) are forecast to grow slower than the German market (21.1% per year).
High Growth Earnings: PHE's earnings are forecast to grow, but not significantly.
Revenue vs Market: PHE's revenue (18.8% per year) is forecast to grow faster than the German market (5.6% per year).
High Growth Revenue: PHE's revenue (18.8% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: PHE's Return on Equity is forecast to be low in 3 years time (14.2%).